Outset Medical Crescita futura
Criteri Future verificati 0/6
Si prevede che Outset Medical aumenterà i profitti e i ricavi rispettivamente del 8.2% e 10.4% all'anno.
Informazioni chiave
8.2%
Tasso di crescita degli utili
n/a
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 17.3% |
| Tasso di crescita dei ricavi | 10.4% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 07 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Jul 14
OM: Index Removal And 2026 Contract Wins Will Support Long-Term Upside
Analysts have reduced their fair value estimate for Outset Medical from $7.00 to $6.00, citing updated views on the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Outset Medical was removed from the Russell 3000 Index and related Russell 3000E, Growth, and Value benchmarks, reducing its presence in a wide group of broad market indices.
Aggiornamento narrativa • Jun 29
OM: HCA Fleet Refresh Agreement Will Support Future Upside
Analysts have trimmed their price target on Outset Medical to $7.67 from $9.00 as they now apply a lower discount rate, slightly adjust future P/E expectations, and update assumptions for revenue growth and profit margins. What’s in the News for Outset Medical Outset Medical was removed from the Russell 3000 Index, which can influence ownership by index tracking funds that previously followed this benchmark.
Aggiornamento narrativa • Jun 15
OM: 2026 Revenue Guidance And Margin Outlook Will Support Long Term Potential
Analysts have revised their price target for Outset Medical to $10.00 from $15.00, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News Outset Medical reiterated earnings guidance for fiscal year 2026, according to a key developments update.Aggiornamento narrativa • Jun 01
OM: Lower Risk Outlook And 2026 Guidance Will Support Long-Term Upside
Analysts have kept their price target for Outset Medical steady at $7.00, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that largely offset each other in their valuation work. What's in the News Outset Medical reiterated earnings guidance for fiscal year 2026 and maintained its outlook for the period.Aggiornamento narrativa • May 18
OM: 2026 Earnings Outlook And Lower Risk Assumptions Support Long-Term Upside
Analysts have raised their price target on Outset Medical to $7.00, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E that they see as better aligning the stock with current fundamentals and risk. What's in the News Outset Medical reiterated earnings guidance for fiscal year 2026, signaling no change to its previously communicated outlook.Aggiornamento narrativa • Apr 24
OM: Cybersecurity Clearance And Next Platform Rollout Will Support Future Upside
Analysts have adjusted their price target for Outset Medical to $9.00 from $10.50, reflecting updated views on fair value, discount rate, profit margin assumptions, and a lower future price-to-earnings (P/E) multiple. What's in the News Outset Medical issued earnings guidance for fiscal 2026, with revenue projected in a range of US$125 million to US$130 million, described as a 5% to 9% change versus US$119.5 million in 2025 (Key Developments).Aggiornamento narrativa • Apr 08
OM: Next Generation Platform And 2026 Outlook Will Support Long Term Potential
Analysts have trimmed their price target on Outset Medical from $17.00 to $15.00, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Outset Medical issued earnings guidance for fiscal 2026, with expected revenue in a range of $125 million to $130 million, compared with $119.5 million in 2025 (company guidance).Aggiornamento narrativa • Mar 25
OM: Cybersecure Platform Clearance Will Drive Future Upside Despite Lowered Multiple
Analysts have revised their price target on Outset Medical to $10.50 from $11.75, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News Outset Medical issued earnings guidance for fiscal year 2026, with projected revenue of $125m to $130m and a stated 5% to 9% change relative to $119.5m in 2025 (Company guidance).Aggiornamento narrativa • Mar 10
OM: Upcoming Cybersecure Platform Rollout Will Support Long-Term Upside
Analysts have modestly adjusted their price target for Outset Medical to $7.00. This reflects updated views on the company’s discount rate, revenue growth outlook, profit margin assumptions, and future P/E expectations.Aggiornamento narrativa • Feb 24
OM: Upcoming Platform Launch And 2026 Outlook Will Support Long-Term Upside
Analysts have reduced their price target on Outset Medical to $7.00 from $7.00, reflecting updated views on a slightly higher discount rate, a small change in modeled revenue growth, a modest improvement in profit margin, and a lower assumed future P/E multiple. What's in the News Outset Medical issued earnings guidance for fiscal 2026, with revenue expected in a range of $125 million to $130 million, compared with $119.5 million in 2025 (Company guidance).Aggiornamento narrativa • Feb 09
OM: Next Cybersecure Platform Will Support Future Upside Despite Reduced Expectations
Analysts have reduced their price target for Outset Medical to $11.75 from $15.75, citing updated expectations around revenue growth, profit margins, and a lower future P/E multiple that collectively point to a more cautious valuation outlook. What's in the News Outset Medical received 510(k) clearance from the U.S. Food and Drug Administration for its next generation Tablo platform, which is designed for use by hospitals, health systems and home dialysis providers (Key Developments).Articolo di analisi • Feb 02
Outset Medical, Inc. (NASDAQ:OM) Held Back By Insufficient Growth Even After Shares Climb 35%
Those holding Outset Medical, Inc. ( NASDAQ:OM ) shares would be relieved that the share price has rebounded 35% in the...Aggiornamento narrativa • Jan 25
OM: Clinical Evidence Will Support Stronger Long-Term Outlook Despite Lower 2025 Guidance
Analysts have modestly adjusted their price target for Outset Medical, citing updated views on discount rates, revenue growth assumptions, profit margins, and future P/E levels as the key drivers of the change. What's in the News Outset Medical revised its 2025 revenue guidance to a range of US$115 million to US$120 million, compared with prior guidance of US$122 million to US$126 million, while maintaining expectations for full year gross margin in the high 30% range (company guidance).Aggiornamento narrativa • Jan 11
OM: Clinical Data Momentum Will Support Long Term Potential
Analysts have cut their price target for Outset Medical from US$39.00 to US$17.00, pointing to updated assumptions for higher discount rates, more moderate revenue growth, slightly different profit margins, and a lower future P/E multiple. What's in the News Outset Medical revised its 2025 revenue guidance to a range of US$115 million to US$120 million, compared with prior guidance of US$122 million to US$126 million, while maintaining expectations for full year gross margin in the high 30% range (company guidance).Aggiornamento narrativa • Dec 25
OM: Clinical Outcome Data Will Support Stronger Long-Term Outlook Despite Lower Guidance
Analysts have reduced their price target on Outset Medical from approximately 17 dollars to about 7 dollars, citing higher perceived risk, slower expected revenue growth, and lower future valuation multiples despite slightly improved margin assumptions. What's in the News Outset Medical lowered its 2025 revenue guidance to a range of 115 million to 120 million dollars, down from its prior outlook of 122 million to 126 million dollars, while reaffirming expectations for gross margin in the high 30 percent range (corporate guidance) The company announced research findings from over 1 million Tablo hemodialysis treatments across more than 600 facilities, showing strong clinical effectiveness in meeting rigorous treatment goals, including for the most critical patients (product related announcement) Five year results from an AdventHealth hospital in Florida using insourced dialysis with Tablo reported a 94 percent reduction in serious cardiac or respiratory events, lower central line bloodstream infections, staff satisfaction above 95 percent, and a reported return on investment within two years (product related announcement) Outset Medical plans to present these Tablo clinical and economic outcomes at the American Society of Nephrology Kidney Week 2025 in Houston, a global forum for kidney care advances (product related announcement) Valuation Changes Fair Value: reduced significantly from 17.0 dollars to 7.0 dollars, implying a materially lower intrinsic equity value estimate.Articolo di analisi • Dec 19
The Market Doesn't Like What It Sees From Outset Medical, Inc.'s (NASDAQ:OM) Revenues Yet As Shares Tumble 27%
Unfortunately for some shareholders, the Outset Medical, Inc. ( NASDAQ:OM ) share price has dived 27% in the last...Aggiornamento narrativa • Dec 11
OM: Clinical Outcomes Data Will Support Future Upside Despite Near Term Guidance Cut
Analysts have modestly raised their price target on Outset Medical to approximately $22 per share from about $21 previously, citing a slightly higher expected future earnings multiple that more than offsets a small downward revision to long term profit margins. What's in the News Lowered 2025 revenue guidance to a range of $115 million to $120 million, down from prior expectations of $122 million to $126 million, while maintaining an outlook for gross margin in the high 30% range (company guidance) Announced new research from over 1 million Tablo hemodialysis treatments across approximately 750 facilities, highlighting the clinical effectiveness of insourced dialysis in meeting rigorous treatment goals, including up to 24 hour treatments for the most critical patients (company announcement) Reported 5 year data from AdventHealth Ocala showing a 94% reduction in serious cardiac or respiratory events, sustained reduction in central line bloodstream infections, nurse retention above 95%, and a strong return on investment within the first two years after insourcing dialysis with Tablo (company announcement) Planned to present these findings at the American Society of Nephrology Kidney Week 2025 in Houston, a major global forum for kidney care innovations attended by more than 12,000 professionals (conference presentation) Valuation Changes The fair value estimate remained unchanged at approximately $15.75 per share, indicating no shift in the long term intrinsic value assessment.Aggiornamento narrativa • Nov 27
OM: Patient Outcomes And Expanding Home Dialysis Access Will Drive Future Upside
Analysts have adjusted Outset Medical's price target to $15.75, maintaining previous expectations as updated evaluations of the company’s discount rate and future earnings metrics led to only minor forecast changes. What's in the News Outset Medical revised its 2025 revenue guidance, lowering it to a range of $115 million to $120 million.Aggiornamento narrativa • Nov 13
OM: Patient Outcomes And Home Dialysis Expansion Will Drive Renewed Upside
Narrative Update on Outset Medical Analyst Price Target Analysts have revised their fair value estimate for Outset Medical downward. The target price has been reduced from $25.75 to $15.75, citing updated financial forecasts and industry reassessments.Articolo di analisi • Sep 23
Outset Medical (NASDAQ:OM) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Sep 22
Outset Medical: Revenue Trajectory Yet To Reflect Favorable Demand Tailwinds
Summary Q2 revenue rose 15%, driven by a 25% increase in console sales and 17% growth in consumables. Q2 gross margin was 38.4%, impacted by temporary headwinds, and should gradually expand towards management's mid-term target of 50%. I expect cash burn this year of $45 million, with break-even likely reached in 2028, supported by gross profit growth significantly outpacing operating expense growth. Though execution risk is high, OM's stock trades at an undemanding valuation, especially compared to relevant peers. I am maintaining a hold rating on the stock. Read the full article on Seeking AlphaArticolo di analisi • Aug 10
Outset Medical, Inc. (NASDAQ:OM) Just Reported And Analysts Have Been Lifting Their Price Targets
NasdaqGS:OM 1 Year Share Price vs Fair Value Explore Outset Medical's Fair Values from the Community and select yours...Aggiornamento narrativa • Aug 08
Decentralized Care And Telehealth Will Advance Dialysis Adoption
Analysts have raised their consensus revenue growth forecast for Outset Medical from 11.8% to 12.6% per annum, offsetting a higher discount rate, and resulting in an increased fair value price target from $24.50 to $25.75. What's in the News Outset Medical raised its 2025 revenue guidance to $122 million-$126 million from $115 million-$125 million.Articolo di analisi • Aug 02
Outset Medical, Inc. (NASDAQ:OM) Might Not Be As Mispriced As It Looks After Plunging 27%
The Outset Medical, Inc. ( NASDAQ:OM ) share price has softened a substantial 27% over the previous 30 days, handing...Articolo di analisi • May 13
Does Outset Medical (NASDAQ:OM) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Apr 16
Outset Medical: The Worst Is Over, But Execution Risk Remains High
Summary Regulatory issues are now behind the company, and demand appears strong, supported by a growing order backlog and promising 2025 revenue guidance. The balance sheet is in good shape, with $210 million in cash and $100 million in debt. The path to profitability hinges on a re-acceleration in growth alongside improving gross margins, with operating expenses remaining largely flat. While the current valuation offers an attractive upside, the risk profile remains elevated. I remain cautious about the stock and assign it a Hold rating. Read the full article on Seeking Alpha
Nuova narrativa • Apr 12
Cost Cuts And Care Expansion Will Secure Success By 2025
Outset Medical's expanding revenue from recurring sources and acute care markets underpins strong future growth prospects and console sales.Articolo di analisi • Apr 08
Take Care Before Diving Into The Deep End On Outset Medical, Inc. (NASDAQ:OM)
With a price-to-sales (or "P/S") ratio of 1.5x Outset Medical, Inc. ( NASDAQ:OM ) may be sending bullish signals at the...Articolo di analisi • Dec 23
A Piece Of The Puzzle Missing From Outset Medical, Inc.'s (NASDAQ:OM) 44% Share Price Climb
Outset Medical, Inc. ( NASDAQ:OM ) shares have continued their recent momentum with a 44% gain in the last month alone...Articolo di analisi • Nov 08
Further Upside For Outset Medical, Inc. (NASDAQ:OM) Shares Could Introduce Price Risks After 32% Bounce
Outset Medical, Inc. ( NASDAQ:OM ) shareholders are no doubt pleased to see that the share price has bounced 32% in the...Articolo di analisi • Sep 24
Outset Medical, Inc. (NASDAQ:OM) Might Not Be As Mispriced As It Looks After Plunging 27%
Unfortunately for some shareholders, the Outset Medical, Inc. ( NASDAQ:OM ) share price has dived 27% in the last...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 153 | N/A | N/A | N/A | 3 |
| 12/31/2027 | 139 | -66 | N/A | N/A | 3 |
| 12/31/2026 | 126 | -73 | N/A | N/A | 3 |
| 6/30/2026 | 118 | -74 | -39 | -38 | N/A |
| 3/31/2026 | 118 | -75 | -34 | -34 | N/A |
| 12/31/2025 | 119 | -82 | -47 | -46 | N/A |
| 9/30/2025 | 120 | -88 | -54 | -53 | N/A |
| 6/30/2025 | 119 | -98 | -68 | -68 | N/A |
| 3/31/2025 | 115 | -114 | -97 | -96 | N/A |
| 12/31/2024 | 114 | -128 | -117 | -116 | N/A |
| 9/30/2024 | 115 | -141 | -126 | -124 | N/A |
| 6/30/2024 | 116 | -159 | -140 | -138 | N/A |
| 3/31/2024 | 125 | -169 | -136 | -133 | N/A |
| 12/31/2023 | 130 | -173 | -135 | -131 | N/A |
| 9/30/2023 | 132 | -176 | -146 | -141 | N/A |
| 6/30/2023 | 129 | -170 | -148 | -142 | N/A |
| 3/31/2023 | 118 | -170 | -160 | -152 | N/A |
| 12/31/2022 | 115 | -163 | -154 | -146 | N/A |
| 9/30/2022 | 112 | -163 | -151 | -144 | N/A |
| 6/30/2022 | 110 | -152 | -143 | -138 | N/A |
| 3/31/2022 | 110 | -139 | -134 | -130 | N/A |
| 12/31/2021 | 103 | -132 | -133 | -130 | N/A |
| 9/30/2021 | 92 | -123 | -128 | -123 | N/A |
| 6/30/2021 | 79 | -135 | -130 | -124 | N/A |
| 3/31/2021 | 66 | -131 | -120 | -113 | N/A |
| 12/31/2020 | 50 | -79 | -108 | -99 | N/A |
| 9/30/2020 | 40 | -67 | -95 | -88 | N/A |
| 6/30/2020 | 29 | -41 | -82 | -76 | N/A |
| 3/31/2020 | 20 | -40 | N/A | -77 | N/A |
| 12/31/2019 | 15 | -85 | N/A | -70 | N/A |
| 12/31/2018 | 2 | -73 | N/A | -46 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che OM rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che OM rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che OM rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di OM ( 10.4% all'anno) crescerà più lentamente rispetto al mercato US ( 13% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di OM ( 10.4% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di OM è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/18 20:28 |
| Prezzo dell'azione a fine giornata | 2026/08/18 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Outset Medical, Inc. è coperta da 8 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Travis Steed | BofA Global Research |
| Amit Hazan | Goldman Sachs |
| Danielle Antalffy | Leerink Partners LLC |